1.Basic info.
 
Product Name:Desmopressin Acetate
CAS:16789-98-3
Purity: 99% min
MF:C46H64N14O12S2
Appearance :White powder
Sequence: Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2
At the N-terminus, H-means Free amine.The C-terminus is the amidation. The-COOH residual has been replaced by -NH2 residual.
Disulfide bridge: Mpa1-Cys6
Molecular Formula: C46H64N14O12S2
Molecular Weight: 1069.24

2.Product Description:

Desmopressin (trade names: DDAVP, DesmoMelt, Minirin, Minirin Melt, Octim, Stimate) is a synthetic replacement for vasopressin, the hormone that reduces urine production. It may be taken nasally, intravenously, or as an oral or sublingual tablet. Physicians prescribe desmopressin most frequently for treatment of diabetes insipidus, bedwetting, or nocturia.

 
3.Product Applications:
 

Doctors prescribe desmopressin frequently for treatment of nocturnal enuresis ( bedwetting ) . It is usually prescribed in the form of oral desmopressin acetate , DDAVP . Patients taking DDAVP are 4.5 times more likely to sleep without disruption compared with placebo .

Desmopressin can be used to promote the release of von Willebrand factor ( with subsequent increase in factor VIII survival secondary to vWF complexing ) in patients with coagulation disorders such as von Willebrand disease, mild hemophilia A ( factor VIII deficiency ) , and thrombocytopenia . It can be used with uremic induced platelet dysfunction . It is not effective in the treatment of hemophilia B ( factor IX deficiency ) , severe hemophilia A , or von Willebrand 2B .

Desmopressin is used in the treatment of central diabetes insipidus ( DI ) , to replace endogenous ADH that is missing in the central nervous system type of this disorder ( decreased production of ADH from the posterior pituitary ) . It is also used in the diagnostic workup for diabetes insipidus , in order to distinguish central from nephrogenic DI .

Desmopressin has some benefit in adults who have problems with night time urination (known as nocturia).
Clotting disorders Desmopressin stimulates the release of von Willebrand factor (vWF) from the Weibel-Palade_body bodies ofendothelial cells, thereby increasing the levels of vWF (as well as coagulant factor VIII) 3 to 5-fold. Desmopressin can be used to promote the release of von Willebrand factor (with subsequent increase in factor VIII survival secondary to vWF complexing) in patients with coagulation disorders such as von Willebrand disease, mild hemophilia A (factor VIII deficiency), and thrombocytopenia. It can be used with uremic induced platelet dysfunction. It is not effective in the treatment of hemophilia B (factor IX deficiency) or severe hemophilia A.